LifeStance Health Group (LFST) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of LifeStance Health Group (NASDAQ: LFST) recently:

• 8/7/2026 – LifeStance Health Group had its price target raised by BTIG Research from $15.00 to $16.00. They now have a “buy” rating on the stock.
• 7/25/2026 – LifeStance Health Group was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/24/2026 – LifeStance Health Group had its price target raised by BTIG Research from $12.00 to $15.00. They now have a “buy” rating on the stock.
• 7/21/2026 – LifeStance Health Group had its price target raised by Canaccord Genuity Group Inc. from $11.00 to $13.00. They now have a “buy” rating on the stock.
• 7/14/2026 – LifeStance Health Group had its price target raised by Barclays PLC from $9.00 to $13.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – LifeStance Health Group was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/13/2026 – LifeStance Health Group had its price target raised by KeyCorp from $11.00 to $13.00. They now have an “overweight” rating on the stock.
• 7/4/2026 – LifeStance Health Group was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/13/2026 – LifeStance Health Group was downgraded by Wall Street Zen from “strong-buy” to “buy”.

Insider Transactions at LifeStance Health Group

In other news, Director Robert Bessler sold 894,337 shares of the company’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the sale, the director owned 539,763 shares of the company’s stock, valued at approximately $5,467,799.19. This represents a 62.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Darren M. Black sold 5,899,661 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the sale, the director owned 23,310,115 shares of the company’s stock, valued at approximately $186,947,122.30. The trade was a 20.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 7,612,394 shares of company stock valued at $62,938,451. 3.50% of the stock is owned by corporate insiders.

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.